Results 171 to 180 of about 23,600 (247)

Cutaneous Epstein-Barr virus-positive polymorphous posttransplantation lymphoproliferative disorder responding to rituximab. [PDF]

JAAD Case Rep
Chen M, Hwang J, Germanas J.
europepmc   +1 more source

Targeting Wnt/β-Catenin Pathway by DNA Alkylating Pyrrole-Imidazole Polyamide in Colon Cancer. [PDF]

Cancer Sci
Shimozato O, Akao N, Yanagisawa Y, Mori Y, Zhang X, Kida Y, Igarashi R, Watanabe T, Ozaki T, Takatori A.   +9 more
europepmc   +1 more source

Chemotherapy-free treatment with acalabrutinib can benefit patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were never treated before: a plain language summary of the ELEVATE-TN study. [PDF]

Future Oncol
Sharman JP, Hakre S.
europepmc   +1 more source

Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia. [PDF]

Blood Adv
Goede V, Fischer K, Robrecht S, Giza A, Dyer MJS, Eckart MJ, Mϋller L, Smolej L, Kutsch N, Fink AM, Stilgenbauer S, Hallek M.   +11 more
europepmc   +1 more source

Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia. [PDF]

Ann Hematol
Morelli F, Linari S, Rapolla CM, Attanasio M, Salvianti F, Sanna A.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

The Lancet Oncology, 2023
BACKGROUND In the GLOW study, fixed-duration ibrutinib-venetoclax showed superior progression-free survival versus chlorambucil-obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia who were older or had comorbidities, or both,
C. Niemann, T. Munir, C. Moreno, Carolyn Owen, G. Follows, O. Benjamini, A. Janssens, M. Levin, Tadeusz Robak, M. Šimkovič, Sergey Voloshin, V. Vorobyev, M. Yağcı, L. Ysebaert, K. Qi, Qianya Qi, Pierre Sinet, Lori Parisi, Srimathi Srinivasan, N. Schuier, K. Baeten, A. Howes, D. B. Caces, A. Kater   +23 more
semanticscholar   +1 more source

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

New England Journal of Medicine, 2014
Javier De La Serna, Stephen Opat, Stephan Stilgenbauer   +2 more
exaly   +2 more sources

Design, synthesis and anticancer evaluation of novel oncolytic peptide-chlorambucil conjugates.

Bioorganic chemistry (Print), 2023
Nitrogen mustards (NMs) are an important class of chemotherapeutic drugs and have been widely employed for the treatment of various cancers. However, due to the high reactivity of nitrogen mustard, most NMs react with proteins and phospholipids within ...
Hao Yin, Xingchuang Fu, Hanxue Gao, Yan-nan Ma, Jing-Fang Yao, Shan-Shan Du, Yun-Kun Qi, Kewei Wang   +7 more
semanticscholar   +1 more source

Glucocorticoids, Cyclosporine, Azathioprine, Chlorambucil, and Mycophenolate in Dogs and Cats: Clinical Uses, Pharmacology, and Side Effects.

The Veterinary clinics of North America. Small animal practice, 2022
The treatment of immune-mediated disease in dogs and cats continues to evolve as new therapies are adapted from human medicine. Glucocorticoids remain the first-line treatment followed by second-line therapies including cyclosporine, azathioprine (dogs),
K. Viviano
semanticscholar   +1 more source